The Industry

September 2008
Pharmaceutical Representative;Sep2008, Vol. 38 Issue 9, p12
The article offers world news briefs related to pharmaceutical industry. Teva Pharmaceutical Industries Ltd. has signed a definitive agreement to acquire Barr Pharmaceuticals Inc. Merck & Co. Inc. has received European Union marketing approval for two combination drugs, the type 2 diabetes treatment Janumet and lipid-modifying therapy Tedaptive. GlaxoSmithKline and Actelion Ltd. will collaborate for the development and commercialization of Actelion's Phase III insomia drug almorexant.


Related Articles

  • Generics market becomes international as M&A activity intensifies. Baltazar, Amanda // Drug Store News;11/17/2008, Vol. 30 Issue 14, p50 

    The article reports that the merger and acquisition in the generic market has intensified in the U.S. Teva Pharmaceutical Industries Ltd.'s proposed purchase of U.S. giant Barr Pharmaceuticals in the biggest merger in the generics industry. According to Glenmark CEO Glenn Saldanha, consolidation...

  • Teva Pharmaceutical to Acquire Barr for $7.46 Billion. Ramesh, Deepti // Chemical Week;7/28/2008, Vol. 170 Issue 23, p23 

    The article reports that Teva Pharmaceutical Industries Ltd. has signed a definitive agreement to acquire specialty pharma firm Barr Pharmaceuticals, the fourth-largest generic drug company worldwide, for about $7.46 billion. Shlomo Yanai, Teva president and chief executive officer (CEO) said...

  • TOP STORIES.  // MondayMorning;11/22/2010, Vol. 18 Issue 43, p1 

    The article offers news briefs related to drug industry in the U.S. Amgen Inc. will acquire Actelion Ltd. A drug from Merck & Co. has helped in minimizing the complications of heart diseases. A gene-therapy treatment called Mydica which has been made by Celladon Corp. has helped patients with...

  • TOP STORIES.  // MondayMorning;7/21/2008, Vol. 16 Issue 28, p1 

    The article presents news items related to the pharmaceutical industry in the U.S. Teva Pharmaceutical Industries Ltd. has agreed to buy Barr Pharmaceuticals Inc. for $7.46 billion. The earnings of Johnson & Johnson has increased by 8% in the second quarter of 2008 as demand for consumer...

  • Around the State.  // njbiz;9/12/2005, Vol. 18 Issue 37, p31 

    Presents news briefs on business in New Jersey as of September 12, 2005. Merger between EpiCept and Maxim Pharmaceuticals; Plans of Barr Pharmaceuticals and Teva Pharmaceutical Industries for the launch of generic versions of the anti-allergy drug Allegra; Development of the first coastal wind...

  • Weaknesses.  // PharmaWatch: CNS;May2012, Vol. 11 Issue 5, p21 

    The article presents an analysis of weaknesses of global provider of generic pharmaceuticals Teva Pharmaceutical Industries Ltd. including limited scope for acquisitions of Barr Laboratories Inc. and Cephalon Inc.

  • Full-Speed Ahead for Teva, Cephalon Deal.  // Pharmaceutical Representative;Nov2011, Vol. 41 Issue 11, p9 

    The article reports the consent order in connection with on hold acquisition of Cephalon, biopharmaceutical company, by Teva Pharmaceutical Industries Ltd., and Teva will also allow nonexclusive U.S. rights to market modafinil tablets.

  • Consolidation Helps Make Big Generics Suppliers Stronger.  // Chain Drug Review;2/12/2010, Vol. 32 Issue 4, p55 

    The article reports on the merger between Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals Inc. to strengthen generics suppliers.

  • REPORTER'S NOTEBOOK. Frederick, James // Drug Store News;4/29/2002, Vol. 24 Issue 6, p21 

    Presents news on the chain pharmacy business in the U.S. as of April 29, 2002. Drug companies that plan to launch free prescription discount card for low-income Medicare members; Approval of Teva Pharmaceutical's capsules for the treatment of patients with very high elevations of serum...


Read the Article


Sign out of this library

Other Topics